Gaois

This is a static copy of data that is exported from IATE on an occasional basis. It should not be assumed that information provided about an entry here will always correspond to the current version of the entry in IATE. That current version can be checked by clicking on the link on the upper right hand side of each entry. More information »

61 results

  1. SOCIAL QUESTIONS|health|pharmaceutical industry
    táirge íocshláinte imscrúdaitheach ardteiripe Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Prüfpräparat für neuartige Therapien
    de
    Definition Prüfpräparat, das ein Arzneimittel für neuartige Therapien im Sinne des Artikels 2 Absatz 1 der Verordnung (EG) Nr. 1394/2007 des Europäischen Parlaments und des Rates ist Reference COM-Internes Dokument SANCO-2012-80155-02-01
    advanced therapy investigational medicinal product | products
    en
    Definition advanced therapy medicinal product [ IATE:2228848 ] which is also an investigational medicinal product [ IATE:2146586 ] Reference COM-EN, based on:Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, CELEX:52012PC0369/EN
    médicament expérimental de thérapie innovante
    fr
    Definition médicament expérimental correspondant à un médicament de thérapie innovante [ IATE:2228848 ] Reference COM-Document interne: SANCO-2012-80155-00-04Règlement relatif aux essais cliniques de médicaments à usage humain
  2. SCIENCE|natural and applied sciences|life sciences · SOCIAL QUESTIONS|health|pharmaceutical industry
    táirge íocshláinte ardteiripe Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Arzneimittel für neuartige Therapien
    de
    Definition die folgenden Humanarzneimittel:- Gentherapeutika gemäß Anhang I Teil IV der Richtlinie 2001/83/EG,- somatische Zelltherapeutika gemäß Anhang I Teil IV der Richtlinie 2001/83/EG,- biotechnologisch bearbeitete Gewebeprodukte gemäß Buchstabe b Reference Verordnung (EG) Nr. 1394/2007 über Arzneimittel für neuartige Therapien CELEX:32007R1394/DE (17.2.2009)
    advanced therapy medicinal product
    en
    Definition any of the following medicinal products for human use:?- a gene therapy medicinal product as defined in Part IV of Annex I to Directive 2001/83/EC, or- a somatic cell therapy medicinal product as defined in Part IV of Annex I to Directive 2001/83/EC,or- ?a tissue engineered product as defined in point (b) of Article 2(1) of Regulation (EC) No 1394/2007 Reference Regulation (EC) No 1394/2007 on advanced therapy medicinal products, Article 2(1)(a), CELEX:02007R1394-20120702/EN
    produit de thérapie innovante | médicament de thérapie innovante
    fr
    Comment notion plus restreinte que celle de produit de thérapie innovante [ IATE:2228511 ]
  3. SOCIAL QUESTIONS|health|pharmaceutical industry
    oibreán frithmhiocróbach Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Context 'Ciallaíonn “frithsheasmhacht in aghaidh ábhair fhrithmhiocróbacha” cumas miocrorgánach teacht slán nó fás áit a bhfuil tiúchan oibreán frithmhiocróbach ar gnách gur leor é chun miocrorgánaigh den speiceas céanna a chosc nó a mharú...' Reference Rialachán (AE) 2019/6 maidir le táirgí íocshláinte tréidliachta agus lena n-aisghairtear Treoir 2001/82/CE, CELEX:32019R0006/GA
    Stoff mit antimikrobieller Wirkung | antimikrobielles Mittel | antimikrobieller Stoff | mikrobenabweisender Stoff | antimikrobieller Wirkstoff | Antimikrobenmittel | antimikrobiell wirkender Stoff
    de
    Definition synthetisch oder auf natürlichem Wege durch Bakterien, Pilze oder Pflanzen erzeugte Biozide, die zur Abtötung von Mikroorganismen - Bakterien, Viren, Pilze und Parasiten, insbesondere Protozoen - oder zur Hemmung ihres Wachstums eingesetzt werden Reference Empfehlung zur umsichtigen Verwendung antimikrobieller Mittel in der Humanmedizin, Erw.1 (ABl. L_34/2002, S.13) CELEX:32002H0077/DE
    Comment umfasst neben Antibiotika IATE:1098823 , Virustatika, Antimykotika, Antiparasitika aber auch Desinfektionsmittel; XREF: Antibiotikum IATE:1098823 ; Antibiotika-Resistenz IATE:1073649 ; Antimikrobielle Resistenz IATE:912591 ; DIV: RSZ, 7.10.09
    antimicrobial substance | antimicrobial medicine | antimicrobial | antimicrobial medicinal product | antimicrobial agent | antimicrobial drug
    en
    Definition any naturally occurring, semi-synthetic or synthetic substance that exhibits antimicrobial activity (kills or inhibits the growth of micro-organisms) and/or the final medicinal product containing such an active substance Reference Directive 2005/25/EC amending Annex VI to Directive 91/414/EEC as regards plant protection products containing micro-organisms
    Comment Includes antibiotics, antivirals, antifungals, anticoccidials and antiprotozoals.
    antimicrobien | substance antimicrobienne | agent anti-microbien | médicament antimicrobien | agent antimicrobien
    fr
    Definition toute substance produite de manière synthétique ou naturelle par des bactéries, des champignons ou des plantes, utilisée pour détruire ou empêcher la croissance de micro-organismes tels que les bactéries, les virus et les champignons, ainsi que des parasites, en particulier les protozoaires Reference Communication de la Commission sur une stratégie communautaire de lutte contre la résistance antimicrobienne CELEX:52001DC0333/FR
  4. SOCIAL QUESTIONS|health|pharmaceutical industry
    táirge íocshláinte cúntach Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Hilfspräparat
    de
    auxiliary medicinal product | auxiliary medicinal products
    en
    Definition medicinal product used in the context of a clinical trial, but not as an investigational medicinal product Reference Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, CELEX:32014R0536/EN
    Comment Auxiliary medicinal products do not include concomitant medications, i.e. medications unrelated to the clinical trial and not relevant for the design of the clinical trial.
    médicament auxiliaire
    fr
    Definition médicament utilisé dans le contexte d'un essai clinique, mais non comme médicament expérimental Reference COM-Document interne: SANCO-2012-80155-00-04Règlement relatif aux essais cliniques de médicaments à usage humain
  5. SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product
    táirge íocshláinte bitheolaíoch Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Biologika | Biologikum | biologisches Arzneimittel | Biopharmakon
    de
    Definition Arzneimittel, dessen Wirkstoff ein biologischer Stoff ist Reference Richtlinie 2003/63/EG der Kommissionzur Änderung der Richtlinie 2001/83/EG zur Schaffung eines Gemeinschaftskodexes für Humanarzneimittel
    biopharmaceutical | biomedicine | biologic | biological medicinal product
    en
    Definition product, the active substance of which is a biological substance Reference CELEX:32003L0063/EN Commission Directive 2003/63/EC amending Directive 2001/83/EC on the Community code relating to medicinal products for human use
    médicament biologique | biomédicament
    fr
    Definition produit dont la substance active est une substance biologique Reference Directive 2003/63/CE de la Commission, CELEX:32003L0063/fr
  6. SOCIAL QUESTIONS|health|pharmaceutical industry
    comhtháirge íocshláinte tréidliachta Reference Rialachán (AE) 2019/6 maidir le táirgí íocshláinte tréidliachta agus lena n-aisghairtear Treoir 2001/82/CE, CELEX:32019R0006/GA Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Tierarzneimittel aus kombinierten Wirkstoffen
    de
    combination veterinary medicinal product
    en
    Definition veterinary medicinal product containing active substances used in the composition of authorised veterinary medicinal products Reference Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC (Text with EEA relevance)
    Comment See also:- combined vaccine
    synergie médicamenteuse | association médicamenteuse
    fr
    Definition regroupement de plusieurs principes actifs dans un même médicament vétérinaire ou association de plusieurs médicaments vétérinaires permettant d'augmenter l'efficacité et de diminuer les doses, donc les risques d'effets indésirables de chacun d'entre eux Reference COM-FR, d’après Le Larousse médical (édition 2006) > association médicamenteuse [14.8.2014]
    Comment Lorsque le contexte ne permet pas de le déduire, on pourra éventuellement préciser «à usage vétérinaire» (COM-FR).À ne pas confondre avec l’interaction médicamenteuse [IATE:1073736 ], qui peut être positive ou négative, voulue ou fortuite.Source: Le Larousse médical (édition 2006) > interaction médicamenteuse [14.8.2014]
  7. SOCIAL QUESTIONS|health|pharmaceutical industry
    comhtháirge íocshláinte ardteiripe Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    combination ATMP | combined advanced therapy medicinal product | combined ATMP
    en
    Definition advanced therapy medicinal product ( IATE:2228848 ) that fulfils the following conditions: – it must incorporate, as an integral part of the product, one or more medical devices within the meaning of Article 1(2)(a) of Directive 93/42/EEC or one or more active implantable medical devices within the meaning of Article 1(2)(c) of Directive 90/385/EEC, and – its cellular or tissue part must contain viable cells or tissues, or – its cellular or tissue part containing non-viable cells or tissues must be liable to act upon the human body with action that can be considered as primary to that of the devices referred to Reference Regulation (EC) No 1394/2007 on advanced therapy medicinal products CELEX:32007R1394/EN Article 2(1)(d)
    médicament combiné de thérapie innovante
    fr
    Definition médicament de thérapie innovante qui satisfait aux conditions suivantes:- il doit incorporer comme partie intégrante un ou plusieurs dispositifs médicaux au sens de l’article 1er, paragraphe 2, point a), de la directive 93/42/CEE, ou bien un ou plusieurs dispositifs médicaux implantables actifs au sens de l’article 1er, paragraphe 2, point c), de la directive 90/385/CEE, et- sa partie cellulaire ou tissulaire doit contenir des cellules ou des tissus viables, ou- sa partie cellulaire ou tissulaire contenant des cellules ou des tissus non viables doit être susceptible d’avoir sur le corps humain une action qui peut être considérée comme essentielle par rapport à celle des dispositifs précités Reference CELEX:32007R1394/fr
  8. AGRICULTURE, FORESTRY AND FISHERIES|agricultural activity|animal health · EUROPEAN UNION · SOCIAL QUESTIONS|health|pharmaceutical industry
    an Coiste um Tháirgí Íocshláinte d'Úsáid Tréidliachta Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Ausschuss für Tierarzneimittel | CVMP
    de
    Definition einer der wissenschaftlichen Ausschüsse der Europäischen Arzneimittel-Agentur, zuständig für die Gutachten zu allen Fragen der Zulässigkeit der nach dem zentralisierten Verfahren eingereichten Dossiers sowie der Erteilung, Änderung, Aussetzung oder des Widerrufs einer Genehmigung für das Inverkehrbringen eines Tierarzneimittels Reference VO 726/2004 Gemeinschaftsverfahren für die Genehmigung, Überwachung und Pharmakovigilanz von Human- und Tierarzneimitteln und zur Errichtung einer Europäischen Arzneimittel-Agentur, Art.30 (ABl. L_136/2004) CELEX:32004R0726
    Comment DIV: AIH 28/05/2004 UPD: ajs 20.9.2006
    CVMP | Committee for Medicinal Products for Veterinary Use | Committee for Veterinary Medicinal Products
    en
    Definition Part of the European Medicines Agency. Responsible for drawing up the Agency's opinion on any question concerning the admissibility of files submitted in accordance with the centralised procedure, the granting, variation, suspension or revocation of an authorisation to place a veterinary medicinal product on the market, and pharmacovigilance. Reference Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, Article 30 CELEX:32004R0726/EN
    comité des médicaments à usage vétérinaire | CVMP | CMV
    fr
    Definition comité chargé de formuler l'avis de l'Agence européenne des médicaments sur toute question concernant la recevabilité des dossiers présentés en suivant la procédure centralisée, l'octroi, la modification, la suspension ou le retrait d'une autorisation de mise sur le marché d'un médicament vétérinaire [...] ainsi que la pharmacovigilance Reference Règlement (CE) n° 726/2004 établissant des procédures communautaires pour l'autorisation et la surveillance en ce qui concerne les médicaments à usage humain et à usage vétérinaire, et instituant une Agence européenne des médicaments, article 30, CELEX:32004R0726/fr
    Comment MISC: Relève de l'Agence européenne des médicaments (IATE:843722 ).
  9. SOCIAL QUESTIONS|health|pharmaceutical industry
    an Coiste um Tháirgí Íocshláinte Dílleachta Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Ausschuß für Arzneimittel für seltene Leiden
    de
    Comment DIV: RSZ 12/03/2003
    COMP | Committee for Orphan Medicinal Products
    en
    Definition Committee set up by Article 4 of Regulation (EC) No 141/2000 on orphan medicinal products; its tasks include examining applications for the designation of a medicinal product as an orphan medicinal product and advising the Commission on the establishment and development of a policy on orphan medicinal products for the European Union Reference Based on Article 4, Regulation (EC) No 141/2000 on orphan medicinal products, CELEX:32000R0141
    Comité des médicaments orphelins
    fr
    Comment institué en vertu de l’article 4 du règlement (CE) n o 141/2000
    COMP
    mul
  10. EUROPEAN UNION|EU institutions and European civil service|EU office or agency|European Medicines Agency · EUROPEAN UNION|EU institutions and European civil service|EU office or agency|committee (EU) · SOCIAL QUESTIONS|health|pharmaceutical industry
    an Coiste um Tháirgí Íocshláinte lena nÚsáid ag an Duine Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Ausschuss für Humanarzneimittel
    de
    Definition Teil der Agentur, zuständig für die Formulierung des Gutachtens der Agentur zu allen Fragen bezüglich der Zulässigkeit der nach dem zentralisierten Verfahren eingereichten Dossiers, der Erteilung, Änderung, Aussetzung oder des Widerrufs einer Genehmigung für das Inverkehrbringen eines Humanarzneimittels [...] sowie bezüglich der Pharmakovigilanz Reference VO 726/2004 Gemeinschaftsverfahren für die Genehmigung und Überwachung von Human- und Tierarzneimitteln und zur Errichtung einer Europäischen Arzneimittel-Agentur, Art.5 (ABl. L_136/2004, S.1) CELEX:32004R0726/DE
    Comment DIV: RSZ 03/12/2002;UPDATED: AIH 28/05/2004; UPD: CHO 26/06/07
    CPMP | Committee for Proprietary Medicinal Products | CHMP | Committee on Medicinal Products for Human Use | Committee for Medicinal Products for Human Use
    en
    Definition Committee attached to the European Medicines Agency and responsible for drawing up the Agency's opinions on, inter alia, the granting, variation, suspension or revocation of an authorisation to place a medicinal product for human use on the market, and pharmacovigilance. Reference Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency
    CPMP | comité des médicaments à usage humain | Comité des spécialités pharmaceutiques | CHMP
    fr
    Definition Comité relevant de l'Agence européenne des médicaments [IATE:843722 ], chargé de formuler l'avis de l'Agence sur, entre autres, la recevabilité, l'octroi, la modification, la suspension ou le retrait d'une autorisation de mise sur le marché d'un médicament à usage humain, ainsi que de la pharmacovigilance. Reference CELEX:32004R0726/FR
    CHMP
    mul
  11. INTERNATIONAL ORGANISATIONS|world organisations · SOCIAL QUESTIONS|health
    cógas góchumtha Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Context 'Níl dabht ar bith ann ach go bhfuil méadú ag teacht ar an líon daoine atá ag ceannach cógas ar líne agus cógas góchumtha agus gur saincheist é seo nach mór do ghníomhaireachtaí rialála ar fud na hEorpa aird a thabhairt air.' Reference 'Tuarascáil Bhliantúil 2007 - Ag Cosaint Sláinte Poiblí agus Ainmhí', an tÚdarás Rialála Táirgí Sláinte, https://www.hpra.ie/docs/default-source/publications-forms/corporate-policy-documents/turarsc%C3%A1il-bhliant%C3%BAil-2007-imb.pdf?sfvrsn=2 [3.2.2016]
    Arzneimittelfälschung
    de
    counterfeit medicine | counterfeit medicinal product
    en
    Definition medicine1 which is deliberately and fraudulently mislabelled with respect to identity and/or source1medicine [ IATE:1443220 ] Reference World Health Organisation > International Medical Products Anti-Counterfeiting Taskforce (IMPACT) > Frequently Asked Questions, http://www.who.int/impact/impact_q-a/en/index.html [4.8.2015] > 5) What are counterfeit medicines?
    Comment 1. WHO's definition is closer to the EU definition of falsified medicine1 than to EU definition of counterfeit medicine2.2. At the present moment, there is considerable ambiguity between the terms 'falsified medicine' and 'counterfeit medicine'. The suggestion has been made that the World Health Organization/International Medical Products Anti-Counterfeiting Taskforce (WHO/IMPACT) definition could be changed to refer to ‘falsified’ rather than ‘counterfeit’ medicines. If that change were made, then the meaning of ‘counterfeit’ medicines would revert to that referred to in the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) - a wilful form of trademark infringement. A possible solution suggested is to exclude trademark issues from the definition of falsification used by WHO, recognising that these are adequately covered by the TRIPS definition of counterfeiting, and that civil trademark infringement is not relevant.1falsified medicine [ IATE:3500876 ]2counterfeit [ IATE:3566118 ]References:1. COM-Terminology Coordination2. Charles Clift, Senior Research Consultant; 'Meeting Summary - Counterfeit, Falsified and Substandard Medicines', Centre on Global Health Security, December 2010 http://www.chathamhouse.org/sites/files/chathamhouse/field/field_document/161210summary.pdf [1.9.2015]
    médicament contrefait | médicaments contrefaçons produit pharmaceutique médical produits pharmaceutiques médicaux | médicament de contrefaçon
    fr
    Definition médicament qui est délibérément et frauduleusement muni d’une étiquette n'indiquant pas son identité et/ou sa source véritable Reference Site de l'OMS, "Médicaments contrefaits - Guide pour l'élaboration de mesures visant à éliminer les médicaments contrefaits", 2000, http://apps.who.int/medicinedocs/fr/d/Jwhozip41f/2.1.html [9.3.2011]
    Comment Il peut s'agir d'une spécialité ou d'un produit générique, et parmi les produits contrefaits, il en est qui contiennent les bons ingrédients ou de mauvais ingrédients, ou bien encore pas de principe actif et il en est d'autres où le principe actif est en quantité insuffisante ou dont le conditionnement a été falsifié.(Source: ibid.)La définition que l’OMS donne de médicament contrefait se rapproche davantage de la notion de médicament faslifié, définie dans la directive 2011/62/UE modifiant la directive 2001/83/CE instituant un code communautaire relatif aux médicaments à usage humain, en ce qui concerne la prévention de l’introduction dans la chaîne d’approvisionnement légale de médicaments falsifiés, que de celle de médicament contrefait telle que définie par l’UE.Voir aussi:médicament falsifié [ IATE:3500876 ]médicament contrefait [ IATE:3566119 ]
  12. SOCIAL QUESTIONS|health|pharmaceutical industry
    táirge íocshláinte imscrúdaitheach diagnóiseach Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    diagnostisches Prüfpräparat
    de
    diagnostic investigational medicinal product
    en
    Definition investigational medicinal product [ IATE:2146586 ] used to make a medical diagnosis Reference COM-EN, based on: COM-Internal document: SANCO-2012-80155-00-01 Regulation on clinical trials on medicinal products for human use
    médicament expérimental de diagnostic
    fr
    Definition médicament expérimental utilisé pour réaliser un diagnostic Reference COM-FR, d'après:COM-Document interne: SANCO-2012-80155-00-04Règlement relatif aux essais cliniques de médicaments à usage humain
  13. SOCIAL QUESTIONS|health|pharmaceutical industry
    éifeachtúlacht Reference Rialachán (AE) Uimh. 1235/2010 lena leasaítear, maidir le cógas-aireachas ar tháirgí íocshláinte lena n-úsáid ag an duine, Rialachán (CE) Uimh. 726/2004 lena leagtar síos nósanna imeachta Comhphobail maidir le húdarú agus maoirseacht táirgí íocshláinte lena n-úsáid ag an duine agus le haghaidh úsáide tréidliachta agus lena mbunaítear Gníomhaireacht Leigheasra Eorpach, agus Rialachán (CE) Uimh. 1394/2007 maidir le táirgí íocshláinte ardteiripe, CELEX:32010R1235/GA Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Context 'I gcás go leor trialacha cliniciúla, áfach, níl ach riosca breise íosta i gceist do shábháilteacht na ndaoine is ábhar, i gcomparáid le gnáthchleachtas cliniciúil. Is amhlaidh atá go háirithe i gcás ina bhfuil an táirge íocshláinte imscrúdaitheach cumhdaithe ag údarú margaíochta, is é sin rinneadh measúnú cheana ar an gcáilíocht, ar an tsábháilteacht agus ar an éifeachtúlacht le linn an nós imeachta um údarú margaíochta nó, mura n-úsáidtear an táirge i gcomhréir le téarmaí an údarú margaíochta, go bhfuil sé fianaise-bhunaithe agus go bhfuil sé á thacú fianaise eolaíoch foilsithe maidir le sábháilteacht agus éifeachtúlacht an táirge sin agus i gcás nach gcothaíonn an idirghabháil ach riosca breise an-teoranta don duine is ábhar gcomparáid le gnáthchleachtas cliniciúil.' Reference Rialachán (AE) Uimh. 536/2014 maidir le trialacha cliniciúla ar tháirgí íocshláinte lena n-úsáid ag an duine, agus lena n-aisghairtear Treoir 2001/20/CE, CELEX:32014R0536/GA
    éifeachtúlacht táirge íocshláinte Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Context 'Tá sé tábhachtach do shábháilteacht na ndaoine is ábhar, sa bhreis ar theagmhais agus frithghníomhartha díobhálacha tromchúiseacha, gur cheart gach teagmhas neamhthuartha a d'fhéadfadh tionchar ábhartha a imirt ar mheasúnú sochair agus riosca ar an táirge íocshláinte nó as a leanfadh athruithe i riarachán táirge íocshláinte nó i stiúradh foriomlán trialach cliniciúla a chur i bhfógra chuig an mBallstát lena mbaineann. Áirítear ar theagmhais neamhthuartha den sórt sin méadú ar an ráta a dtarlaíonn frithghníomhartha díobhálacha tromchúiseacha tuartha a bhféadfadh tábhacht chliniciúil a bheith ag baint leo, guais shuntasach ar an bpobal othar, amhail easpa éifeachtúlachta táirge íocshláinte nó mórfhionnachtana sábháilteachta ó staidéar ar ainmhithe a tugadh chun críche le deireanas (amhail carcanaigineacht).' Reference Rialachán (AE) Uimh. 536/2014 maidir le trialacha cliniciúla ar tháirgí íocshláinte lena n-úsáid ag an duine, agus lena n-aisghairtear Treoir 2001/20/CE, CELEX:32014R0536/GA
    éifeachtacht Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Wirkung | Wirksamkeit
    de
    efficacy of a medicinal product | efficacy
    en
    Definition measurement of a medicine's desired effect under ideal conditions, such as in a clinical trial Reference European Medicines Agency (EMA). Glossary > Efficacy (13.11.2020)
    efficacité
    fr
  14. SOCIAL QUESTIONS|health|pharmaceutical industry
    táirgí atá cosúil go bunúsach Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    essentially similar medicinal product | essentially similar product
    en
    Definition a medicinal product is essentially similar to an original product where it satisfies the criteria of having the same qualitative1 and quantitative composition2 in terms of active substances3, of having the same pharmaceutical form4, and of being bioequivalent5 unless it is apparent in the light of scientific knowledge that it differs from the original product as regards safety and efficacy1 qualitative composition [ IATE:3518736 ]2 quantitative composition [ IATE:3518738 ]3 active substance [ IATE:35093 ]4 pharmaceutical form [ IATE:1106950 ]5 bioequivalence [ IATE:1090485 ] Reference European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London, 14 December 2000, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003519.pdf [22.1.2014]
    Comment This term was used in the Abridged Procedure for Generic Medicines up until 2005. "Essential similarity", however, was not defined in Community legislation, and remained a source of legal conflict. After 2005, the requirement of essential similarity was incorporated into the definition of generic medicinal product [ IATE:766172 ] CELEX:02001L0083-20121116/EN . Note ref: Shorthose S., Bird & Bird Llp; 'Guide to EU Pharmaceutical Regulatory Law'. Kluwer Law International, 2011. ISBN: 9041136584, 9789041136589. http://books.google.be/books?id=GBhGIFGml5kC&pg=PA228&dq=essentially+similar+medicinal+generic+product&hl=en&sa=X&ei=rIcEVMGZKsmKOOP-gMgH&ved=0CB4Q6AEwAA#v=onepage&q=essentially%20similar%20medicinal&f=false [01.09.2014]
  15. EUROPEAN UNION|EU institutions and European civil service|EU office or agency|European Medicines Agency · SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product · SOCIAL QUESTIONS|health|pharmaceutical industry|veterinary medicinal product
    Foclóir Táirgí Íocshláinte an Aontais Eorpaigh Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    EU-Arzneimittelverzeichnis
    de
    EU Medicinal Product Dictionary | Article 57 database | Article 57 EU product database | xEVMPD | Extended EudraVigilance Medicinal Product Dictionary
    en
    Definition extended version of the EVMPD medicinal product dictionary fed by marketing authorisation holders with product-related data on all medicinal products authorised in the European Economic Area, including product names, the authorisation holder and relevant pharmacovigilance system, the type and status of the authorisation, pharmaceutical formulation and strength, and the route of administration, as well as active ingredients and excipients Reference COM-EN and COM-Terminology Coordination, based on: Opinion of the European Economic and Social Committee on the ‘Proposal for a Regulation of the European Parliament and of the Council on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use’ COM(2013) 472 final — 2013/0222 (COD)
  16. EUROPEAN UNION|EU institutions and European civil service|EU office or agency · SOCIAL QUESTIONS|health|pharmaceutical industry
    gníomhaireacht measúnú táirge íochshláinte, GLE
    ga
    EMEA Reference Interinstitutional Style Guide 9.5.3 (a) on unique abbreviations for all linguistic versions. http://publications.europa.eu/code/en/en-390500.htm09/09/2009 ;Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    an Ghníomhaireacht Leigheasra Eorpach Reference Togra le haghaidh Rialacháin ón gComhairle lena leasaítear Rialachán (CE) Uimh. 297/95 maidir le táillí is iníoctha leis an nGníomhaireacht Leigheasra Eorpach mar aon le nóta faisnéise míniúcháin. COM (2005) 106.
    ga
    EMA Reference https://europa.eu/european-union/about-eu/agencies/ema_ga
    ga
    Context Déanann an Ghníomhaireacht Leigheasra Eorpach (EMA) sláinte an duine agus sláinte ainmhithe a chosaint agus a chur chun cinn trí mheastóireacht agus monatóireacht a dhéanamh ar leigheasanna laistigh den Aontas Eorpach (AE) agus den Limistéar Eorpach Eacnamaíoch (LEE). Reference https://europa.eu/european-union/about-eu/agencies/ema_ga
    EMA | Agentur Beurteilung Arzneimitteln | Europäische Arzneimittel-Agentur | EMEA | Europäische Agentur für die Beurteilung von Arzneimitteln
    de
    Definition dezentrale Einrichtung der Europäischen Union für die Beurteilung und Überwachung von Human- und Tierarzneimitteln Reference Europ. Kommission http://europa.eu/agencies/community_agencies/emea/index_de.htm
    EMEA | European Medicines Evaluation Agency | European Agency for the Evaluation of Medicinal Products | EAMA | EMA | European Medicines Agency
    en
    Definition agency, established by Regulation (EEC) No 2309/93 of 22 July 1993 and renamed by Regulation (EC) No 726/2004, which is responsible for coordinating the existing scientific resources put at its disposal by Member States for the evaluation, supervision and pharmacovigilance of medicinal products Reference COM-EN, based on:- Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products, CELEX:31993R2309/EN - Regulation (EC) No 726/2004 of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, CELEX:32004R0726/EN
    médicament pour l'évaluation | Agence européenne pour l'évaluation des médicaments | Agence européenne des médicaments | AEM AEEM | EMEA | EMA
    fr
    Definition agence de l'UE chargée de coordonner les ressources scientifiques existantes mises à sa disposition par les États membres en vue de l'évaluation, de la surveillance et de la pharmacovigilance des médicaments Reference Règlement (CE) no 726/2004 du Parlement européen et du Conseil du 31 mars 2004 établissant des procédures de l'Union pour l'autorisation et la surveillance en ce qui concerne les médicaments à usage humain et à usage vétérinaire, et instituant une Agence européenne des médicaments (Texte présentant de l'intérêt pour l'EEE)Texte présentant de l'intérêt pour l'EEE
  17. EUROPEAN UNION|EU institutions and European civil service|EU office or agency|European Medicines Agency · SOCIAL QUESTIONS|health|health policy|organisation of health care|public health
    grúpa stiúrtha feidhmiúcháin Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Context 'Maidir le táirgí íocshláinte, ba cheart grúpa stiúrtha feidhmiúcháin a bhunú laistigh den Ghníomhaireacht chun freagairt láidir ar mhórimeachtaí a áirithiú agus chun gníomhaíochtaí práinneacha laistigh den Aontas a chomhordú maidir leis na saincheisteanna a bhaineann le soláthar táirgí íocshláinte a bhainistiú. Ba cheart don Ghrúpa Stiúrtha liostaí de tháirgí íocshláinte criticiúla a bhunú chun faireachán ar na táirgí sin a áirithiú agus ba cheart dó a bheith in ann comhairle a sholáthar maidir leis an ngníomhaíocht is gá a dhéanamh chun cáilíocht, sábháilteacht, agus éifeachtúlacht táirgí íocshláinte a choimirciú agus chun ardleibhéal cosanta do shláinte an duine a áirithiú.' Reference Togra le haghaidh Rialachán maidir le ról treisithe don Ghníomhaireacht Leigheasra Eorpach in ullmhacht agus bainistiú géarchéimeanna do tháirgí íocshláinte agus d’fheistí leighis, CELEX:52020PC0725/GA
    Grúpa Stiúrtha Leigheasra Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Grúpa Stiúrtha Feidhmiúcháin um Ghanntanais Táirgí Leighis agus um Shábháilteacht Táirgí Leighis Reference Togra le haghaidh Rialachán maidir le ról treisithe don Ghníomhaireacht Leigheasra Eorpach in ullmhacht agus bainistiú géarchéimeanna do tháirgí íocshláinte agus d’fheistí leighis, CELEX:52020PC0725/GA Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Grúpa Stiúrtha Feidhmiúcháin um Ghanntanais agus Sábháilteacht Táirgí Íocshláinte Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Context 'Ba cheart don Ghrúpa Stiúrtha Feidhmiúcháin um Ghanntanais agus Sábháilteacht Táirgí Íocshláinte tairbhiú de thaithí fhairsing eolaíochta na Gníomhaireachta maidir le meastóireacht agus maoirseacht ar tháirgí íocshláinte agus ba cheart dó ról ceannasach na Gníomhaireachta i ndáil le comhordú agus tacaíocht don fhreagairt ar ghanntanais le linn phaindéim COVID‑19 a fhorbairt a thuilleadh.' Reference Togra le haghaidh Rialachán maidir le ról treisithe don Ghníomhaireacht Leigheasra Eorpach in ullmhacht agus bainistiú géarchéimeanna do tháirgí íocshláinte agus d’fheistí leighis, CELEX:52020PC0725/GA
    hochrangige Lenkungsgruppe | hochrangige Lenkungsgruppe der EU zur Überwachung möglicher Engpässe bei Arzneimitteln aufgrund von Großereignissen | Hochrangige Lenkungsgruppe zur Überwachung möglicher Engpässe bei Arzneimitteln und zur Sicherheit von Arzneimitteln | Lenkungsgruppe für Arzneimittel
    de
    Definition von der Kommission gemeinsam mit den Mitgliedstaaten und der Europäischen Arzneimittel-Agentur eingesetztes Gremium mit der Aufgabe, mögliche Engpässe bei Arzneimitteln aufgrund von COVID-19 zu überwachen Reference MITTEILUNG DER KOMMISSION AN DAS EUROPÄISCHE PARLAMENT, DEN EUROPÄISCHEN RAT, DEN RAT, DIE EUROPÄISCHE ZENTRALBANK, DIE EUROPÄISCHE INVESTITIONSBANK UND DIE EURO-GRUPPE Die koordinierte wirtschaftliche Reaktion auf die COVID-19-Pandemie
    executive steering group | Medicines Steering Group | Executive Steering Group on Shortages and Safety of Medicinal Products | MSSG | Medicine Shortages Steering Group | EU Executive Steering Group on shortages of medicines caused by major events | Executive Steering Group on Shortages and Safety of Medicines
    en
    Definition group set up by the European Medicines Agency, the European Commission and national competent authorities in the EU Member States, to monitor potential shortages of medicines caused by major events Reference COM-Terminology Coordination, based on:Communication - Coordinated economic response to the COVID-19 Outbreak, COM/2020/112 finalEuropean Medicines Agency > News & events > News and press releases > 10/03/2020 > Addressing the potential impact of novel coronavirus disease (COVID-19) on medicines supply in the EU (12.5.2021)
    groupe de pilotage exécutif | groupe de pilotage exécutif de l’Union sur les pénuries de médicaments causées par des événements majeurs | groupe de pilotage exécutif sur les pénuries et l’innocuité des médicaments
    fr
    Definition groupe mis sur pied par la Commission européenne avec l’Agence européenne des médicaments et les États membres dans le but de suivre l’évolution d’éventuelles pénuries de médicaments entraînées par la pandémie de COVID-19 Reference COM-FR, d'après:COMMUNICATION DE LA COMMISSION Réaction économique coordonnée à la flambée de COVID-19 (COM/2020/112 final)
    Comment Dans le contexte du nouveau coronavirus, ce comité de pilotage, présidé par la Commission européenne, doit définir et coordonner les actions européennes de protection des patients face au risque de ruptures de stock de médicaments, par exemple lorsque des sites de fabrication sont temporairement fermés ou lorsque des matières premières ou finies ne peuvent être exportées. Ce comité est également chargé d'assurer une information complète et transparente aussi bien des patients que des professionnels de santé.
  18. SOCIAL QUESTIONS|health|pharmaceutical industry
    substaint ghníomhach fhalsaithe a úsáidtear mar ábhair thosaigh i dtáirgí íocshláinte tréidliachta Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Context 'Maidir le gníomhaithe tríú páirtí atá bainteach le dea-chleachtas dáileachán do shubstaintí gníomhacha a úsáidtear mar ábhair thosaigh i dtáirgí íocshláinte tréidliachta, ba cheart do na gníomhaithe sin cloí le ranna ábhartha an dea-chleachtais dáileacháin do shubstaintí gníomhacha a úsáidtear mar ábhair thosaigh i dtáirgí íocshláinte tréidliachta agus ba cheart ranna ábhartha an dea-chleachtais a bheith mar chuid dá n-oibleagáidí conarthacha. Ní mór do na comhpháirtithe uile sa slabhra soláthair cur chuige comhsheasmhach a chleachtadh ionas go mbeidh rath ar an gcomhrac i gcoinne substaintí gníomhacha falsaithe a úsáidtear mar ábhair thosaigh i dtáirgí íocshláinte tréidliachta.' Reference Rialachán Cur Chun Feidhme (AE) 2021/1280 maidir le bearta i ndáil le dea-chleachtas dáileacháin do shubstaintí gníomhacha a úsáidtear mar ábhair thosaigh i dtáirgí íocshláinte tréidliachta i gcomhréir le Rialachán (AE) 2019/6 ó Pharlaimint na hEorpa agus ón gComhairle, CELEX:32021R1280/GA
    substaint ghníomhach fhalsaithe Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Definition aon substaint ghníomhach a úsáidtear mar ábhar tosaigh i dtáirgí íocshláinte tréidliachta a bhfuil léiriú bréagach ann ar aon cheann díobh seo a leanas: (i) an sainaitheantas a bhaineann léi, lena n-áirítear an phacáistíocht agus an lipéadú, an t-ainm atá uirthi nó an comhdhéanamh maidir le haon cheann de na comhábhair agus neart na gcomhábhar thar a chéile; (ii) foinse na substainte, lena n-áirítear an monaróir, tír a monaraíochta, tír a tionscnaimh; nó (iii) stair na substainte, lena n-áirítear na taifid agus na doiciméid a bhaineann leis na bealaí dáileacháin a úsáideadh Reference Rialachán Cur Chun Feidhme (AE) 2021/1280 maidir le bearta i ndáil le dea-chleachtas dáileacháin do shubstaintí gníomhacha a úsáidtear mar ábhair thosaigh i dtáirgí íocshláinte tréidliachta i gcomhréir le Rialachán (AE) 2019/6 ó Pharlaimint na hEorpa agus ón gComhairle, CELEX:32021R1280/GA
    falsified active substance used as a starting material in veterinary medicinal products
    en
    Definition active substance used as a starting material in veterinary medicinal products with a false representation of any of the following: (i) its identity, including its packaging and labelling, its name or its components as regards any of the ingredients and the strength of those ingredients;(ii) its source, including its manufacturer, its country of manufacturing, its country of origin; or(iii) its history, including the records and documents relating to the distribution channels used. Reference Commission Implementing Regulation (EU) 2021/1280 as regards measures on good distribution practice for active substances used as starting materials in veterinary medicinal products in accordance with Regulation (EU) 2019/6
  19. EUROPEAN UNION · PRODUCTION, TECHNOLOGY AND RESEARCH|research and intellectual property|intellectual property · PRODUCTION, TECHNOLOGY AND RESEARCH|research and intellectual property|intellectual property|industrial property|industrial counterfeiting · SOCIAL QUESTIONS|health|pharmaceutical industry
    cógas leighis falsaithe Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    gefälschtes Arzneimittel
    de
    Definition Arzneimittel, bei dem Folgendes gefälscht wurde:a) seine Identität, einschließlich seiner Verpackung und Kennzeichnung, seines Namens oder seiner Zusammensetzung in Bezug auf jegliche Inhaltsstoffe, einschließlich der Arzneiträgerstoffe und des Gehalts dieser Inhaltsstoffe; b) seine Herkunft, einschließlich Hersteller, Herstellungsland, Herkunftsland und Inhaber der Genehmigung für das Inverkehrbringen; oder c) seine Herkunft, einschließlich der Aufzeichnungen und Dokumente in Zusammenhang mit den genutzten Vertriebswegen Reference Richtlinie 2011/62/EU des Europäischen Parlaments und des Rates vom 8. Juni 2011 zur Änderung der Richtlinie 2001/83/EG zur Schaffung eines Gemeinschaftskodexes für Humanarzneimittel hinsichtlich der Verhinderung des Eindringens von gefälschten Arzneimitteln in die legale Lieferkette CELEX:32011L0062/DE
    falsified medical product | false representation of a medical product | falsified medicinal products | falsified medicinal product | falsified medical products | falsified medicine | false representation of a medicinal product
    en
    Definition medicinal product with a false representation of: (a) its identity, including its packaging and labelling, its name or its composition as regards any of the ingredients including excipients and the strength of those ingredients; (b) its source, including its manufacturer, its country of manufacturing, its country of origin or its marketing authorisation holder; or (c) its history, including the records and documents relating to the distribution channels used Reference Directive 2011/62/EU amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products, CELEX:32011L0062/EN
    Comment See also:- counterfeit medicine in the EU [ IATE:3566118 ]- counterfeit medicine according to WHO [ IATE:3566119 ]
    médicament falsifié
    fr
    Definition tout médicament comportant une fausse présentation de:a) son identité, y compris de son emballage et de son étiquetage, de sa dénomination ou de sa composition s’agissant de n’importe lequel de ses composants, y compris les excipients, et du dosage de ces composants;b) sa source, y compris de son fabricant, de son pays de fabrication, de son pays d’origine ou du titulaire de son autorisation de mise sur le marché;ou c) son historique, y compris des enregistrements et des documents relatifs aux circuits de distribution utilisés Reference Directive 2011/62/UE modifiant la directive 2001/83/CE instituant un code communautaire relatif aux médicaments à usage humain, en ce qui concerne la prévention de l’introduction dans la chaîne d’approvisionnement légale de médicaments falsifiés, CELEX:32011L0062/FR
    Comment Le terme «médicament falsifié» est défini dans la directive 2011/62/Union européenne de manière à distinguer clairement les médicaments falsifiés des autres médicaments illégaux, ainsi que des produits portant atteinte aux droits de propriété intellectuelle. La falsification est en effet l’«action d’altérer volontairement (une substance ou tout autre élément) en vue de tromper». Le choix du terme «falsification» sera préféré à celui de «contrefaçon» pour mettre l’accent sur les risques d’atteinte à la santé publique (« contrefaçon » ayant une connotation plus juridique insistant sur la notion d’atteinte aux droits de propriété intellectuelle).(Source: COM-FR d’après: a) la directive 2011/62/UE modifiant la directive 2001/83/CE instituant un code communautaire relatif aux médicaments à usage humain, en ce qui concerne la prévention de l’introduction dans la chaîne d’approvisionnement légale de médicaments falsifiés, cinquième considérant, CELEX:32011L0062/FR ; b) Site de l’Institut international de recherche anti-contrefaçon de médicaments, Définition de la falsification de médicaments, http://www.iracm.com/falsification/definition/ [2.10.2015])Voir aussi: médicament contrefait défini selon l'UE [ IATE:3566118 ] et selon l'OMS [ IATE:3566119 ]